A patient on warfarin has an International Normalized Ratio (INR) of 1.6; what should be done?

Management of INR 1.6 in a Patient on Warfarin

Increase the warfarin dose and recheck the INR within 1-2 weeks. An INR of 1.6 is subtherapeutic for all standard warfarin indications and places the patient at risk for thromboembolic events without providing adequate anticoagulation protection.

Understanding the Therapeutic Context

The therapeutic INR range for most warfarin indications is 2.0-3.0 1. Your patient's INR of 1.6 falls below this target, meaning they are inadequately anticoagulated. According to the American Heart Association/American College of Cardiology guidelines, when the INR is below the therapeutic range, the warfarin dose should be increased 2.

Specific Management Steps

Immediate Action

• Increase the weekly warfarin dose by 10-15% (adjust the total weekly dose, not just a single day)
• This modest increase is appropriate for an INR that is close to, but below, the therapeutic range
• Avoid large dose adjustments that could overshoot and cause supratherapeutic INR 3

Follow-up Monitoring

• Recheck INR in 5-7 days after the dose adjustment
• More frequent monitoring (2-4 times per week) may be needed until the INR stabilizes in the therapeutic range 3
• Once stable, you can gradually extend the interval between tests up to 4-6 weeks 3

Critical Considerations

Assess for Contributing Factors

Before simply increasing the dose, investigate why the INR dropped:

• Medication changes: New drugs that induce warfarin metabolism (antibiotics, antifungals, anticonvulsants) 1
• Dietary changes: Increased vitamin K intake (leafy greens, nutritional supplements)
• Compliance issues: Missed doses or irregular dosing
• Drug interactions: Recent addition of medications that decrease warfarin effect 1

Risk Assessment

An INR of 1.6 is particularly concerning for:

• Mechanical heart valves (especially mitral position): These patients need INR 2.5-3.5 and are at high risk for valve thrombosis 1
• Atrial fibrillation with high stroke risk: Inadequate protection from thromboembolic events 1
• Recent venous thromboembolism: Risk of recurrent thrombosis 1

Common Pitfalls to Avoid

1. Don't wait and recheck without adjusting the dose - While the ACCP guidelines suggest watchful waiting for slightly out-of-range INRs (1.5-1.99), this applies more to INRs closer to 2.0. An INR of 1.6 requires dose adjustment 4

2. Don't make excessive dose changes - Increasing by more than 20% of the weekly dose risks overshooting into supratherapeutic range 3

3. Don't use loading doses - These increase bleeding risk without providing better protection 1, 3

4. Don't forget to document the indication - The target INR varies by indication (2.0-3.0 for most, 2.5-3.5 for mechanical mitral valves) 1

Bridging Considerations

For high-risk patients (mechanical heart valves, recent VTE within 3 months, history of thrombosis while anticoagulated), consider:

• Therapeutic-dose low molecular weight heparin (LMWH) as a bridge until INR reaches therapeutic range
• This is particularly important if the patient has been subtherapeutic for several days 2

However, for most patients with atrial fibrillation or remote VTE, bridging is not necessary for an INR of 1.6 - simply adjust the warfarin dose and monitor closely.

Documentation

Document in the chart:

• Current INR value and date
• Warfarin indication and target INR range
• New warfarin dosing schedule (specify daily doses for the week)
• Date for INR recheck
• Any contributing factors identified
• Patient education provided about compliance and dietary consistency